Department of Pathology, State University of New York Downstate Medical Center, Brooklyn, 11203, USA.
Arch Pathol Lab Med. 2012 Jan;136(1):14-9. doi: 10.5858/arpa.2010-0536-OA.
The number of clinical laboratories introducing various molecular tests to their existing test menu is continuously increasing. Prior to offering a US Food and Drug Administration-approved test, it is necessary that performance characteristics of the test, as claimed by the company, are verified before the assay is implemented in a clinical laboratory.
To provide an example of the verification of a specific qualitative in vitro diagnostic test: cystic fibrosis carrier testing using the Luminex liquid bead array (Luminex Molecular Diagnostics, Inc, Toronto, Ontario).
The approach used by an individual laboratory for verification of a US Food and Drug Administration-approved assay is described.
Specific verification data are provided to highlight the stepwise verification approach undertaken by a clinical diagnostic laboratory.
Protocols for verification of in vitro diagnostic assays may vary between laboratories. However, all laboratories must verify several specific performance specifications prior to implementation of such assays for clinical use. We provide an example of an approach used for verifying performance of an assay for cystic fibrosis carrier screening.
越来越多的临床实验室将各种分子检测引入到现有的检测项目中。在提供美国食品和药物管理局批准的检测之前,有必要在临床实验室实施该检测之前,对公司声称的检测的性能特征进行验证。
提供一个特定的体外诊断测试验证的例子:使用 Luminex 液体珠阵列(Luminex Molecular Diagnostics,Inc.,安大略省多伦多)进行囊性纤维化携带者测试。
描述了一个实验室用于验证美国食品和药物管理局批准的检测的方法。
提供了具体的验证数据,突出了临床诊断实验室所进行的逐步验证方法。
体外诊断检测验证的方案可能因实验室而异。然而,在将这些检测用于临床应用之前,所有实验室都必须验证几个特定的性能规格。我们提供了一个用于验证囊性纤维化携带者筛查检测性能的方法的例子。